960 related articles for article (PubMed ID: 10322128)
1. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
[TBL] [Abstract][Full Text] [Related]
2. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
3. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
4. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
6. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
7. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
8. Effect of growth and maturation on membrane-initiated actions of 1,25-dihydroxyvitamin D3-II: calcium transport, receptor kinetics, and signal transduction in intestine of female chickens.
Larsson B; Nemere I
J Cell Biochem; 2003 Dec; 90(5):901-13. PubMed ID: 14624450
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
10. Homologous up-regulation of vitamin D receptors is tissue specific in the rat.
Gensure RC; Antrobus SD; Fox J; Okwueze M; Talton SY; Walters MR
J Bone Miner Res; 1998 Mar; 13(3):454-63. PubMed ID: 9525346
[TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity.
Bouillon R; Allewaert K; Xiang DZ; Tan BK; van Baelen H
J Bone Miner Res; 1991 Oct; 6(10):1051-7. PubMed ID: 1796753
[TBL] [Abstract][Full Text] [Related]
13. Role of vitamin D3 receptor in the synergistic differentiation of WEHI-3B leukemia cells by vitamin D3 and retinoic acid.
Li J; Finch RA; Sartorelli AC
Exp Cell Res; 1999 Jun; 249(2):279-90. PubMed ID: 10366427
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor ligands for osteoporosis.
Cheskis BJ; Freedman LP; Nagpal S
Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells.
Capiati DA; Rossi AM; Picotto G; Benassati S; Boland RL
J Cell Biochem; 2004 Oct; 93(2):384-97. PubMed ID: 15368364
[TBL] [Abstract][Full Text] [Related]
16. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells.
Kong J; Li YC
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E916-24. PubMed ID: 16368784
[TBL] [Abstract][Full Text] [Related]
18. Analogs of 1alpha,25-dihydroxyvitamin D3 with high potency in induction of osteoclastogenesis and prevention of dendritic cell differentiation: synthesis and biological evaluation of 2-substituted 19-norvitamin D analogs.
Shimazaki M; Miyamoto Y; Yamamoto K; Yamada S; Takami M; Shinki T; Udagawa N; Shimizu M
Bioorg Med Chem; 2006 Jul; 14(13):4645-56. PubMed ID: 16513359
[TBL] [Abstract][Full Text] [Related]
19. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
20. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction.
Eelen G; Verlinden L; Rochel N; Claessens F; De Clercq P; Vandewalle M; Tocchini-Valentini G; Moras D; Bouillon R; Verstuyf A
Mol Pharmacol; 2005 May; 67(5):1566-73. PubMed ID: 15728261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
